Rubiacetate

1. Pharmacodynamics: This drug is a chemically synthesized derivative of madder acid, the active ingredient of the traditional Chinese medicine madder. It is a leukocyte-raising drug created and synthesized in my country. It has the effects of increasing peripheral blood leukocytes, promoting the proliferation and differentiation of hematopoietic stem cells, and having a certain protective effect on hematopoietic stem cells. 6-8 hours after oral administration to mice and dogs, a significant increase in peripheral blood leukocytes was observed. It can also promote the proliferation and differentiation of mouse bone marrow hematopoietic stem cells, and prevent and treat canine leukopenia caused by cyclophosphamide. 2. Pharmacokinetics: Peak blood drug concentration is reached 5-6 hours after taking the drug. It is mainly distributed in the blood, liver, spleen, kidney, muscle, fat and bone. It is excreted with feces and urine, and there is no drug accumulation effect.

This product is a sugar-coated tablet, which appears off-white after removing the sugar coating.

It is suitable for leukocytopenia caused by various reasons. For example, leukocytopenia caused by tumor radiotherapy and chemotherapy, radiation from X-rays and other radioactive substances, benzene poisoning, taking certain antipyretic and analgesic drugs, certain infectious diseases, and leukocytopenia caused by some unknown reasons. It is also used to prevent and treat recurrent hematuria and menorrhagia in women.

Oral administration: 4 tablets at a time, 3 times a day. Take after meals.

A small number of patients experience symptoms such as dry mouth, headache, fatigue, and nausea after taking the medicine.

Keep tightly closed in a cool, dark and dry place.

Tentative 24 months

Shandong FANGMING Pharmaceutical Group Co., Ltd.

• Founded in:

  2000-07-07

• Address:

  Fangming Section, Huanghe Road, Dongming County, Shandong Province

• Tax NO.:

  91371700724268643E

• Registered Funds:

  216.829902 yuan

• Website:

  Log in to view

• Email:

  Log in to view